

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (cancelled)

2. (currently amended) An isolated nucleic acid encoding a polypeptide comprising ~~an amino acid sequence set forth in~~ SEQ ID NO:111, with the exception that the ~~amino acid sequence~~ polypeptide contains an amino acid change which results from a single nucleotide polymorphism of guanine to adenine at position 21 set forth in SEQ ID NO.: 5969.

3-4. (cancelled)

5. (currently amended) An isolated nucleic acid comprising ~~a nucleotide sequence as set forth in~~ SEQ ID NO.:19, with the exception that the ~~nucleotide sequence~~ nucleic acid contains a single nucleotide polymorphism of guanine to adenine at position 21 of SEQ ID NO.: 5969.

6. (cancelled)

7. (original) An isolated nucleic acid comprising a nucleotide sequence which is 90% identical to the nucleotide sequence according to claim 5.

8-10 (cancelled)

11. (currently amended) An isolated nucleic acid comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid according to claim ~~[[9]]~~ 5.

12-14. (cancelled)

15. (currently amended) A vector comprising the nucleic acid according to claim [[4]] 2.

16. (currently amended) A vector comprising the nucleic acid according to claim [[9]] 5.

17. (cancelled)

18. (currently amended) An isolated host cell comprising the vector according to claim [[14]] 15, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.

19. (currently amended) An isolated host cell comprising the vector according to claim [[15]] 16, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.

20-30. (cancelled)

31. (original) A pharmaceutical composition comprising the nucleic acid according to claim 11, and a physiologically acceptable carrier, excipient, or diluent.

32-33. (cancelled)

34. (currently amended) A pharmaceutical composition comprising the vector according to claim [[14]] 15, and a physiologically acceptable carrier, excipient, or diluent.

35. (currently amended) A pharmaceutical composition comprising the vector according to claim [[15]] 16, and a physiologically acceptable carrier, excipient, or diluent.

36-41. (cancelled)

42-46. (cancelled)

47-55. (cancelled)

56. (currently amended) A kit for detecting a 12q23-qter nucleotide sequence comprising:

a) the isolated nucleic acid according to claim [[9]] 2; and

b) at least one component to detect hybridization of the isolated nucleic acid to a 12q23-qter nucleotide sequence.

57. (currently amended) A kit for detecting a 12q23-qter nucleotide sequence comprising:

a) the isolated nucleic acid according to claim [[11]] 5; and

b) at least one component to detect hybridization of the isolated nucleic acid to a 12q23-qter nucleotide sequence.

58. (currently amended) A kit for detecting a 12q23-qter nucleotide sequence comprising:

a) the isolated nucleic acid according to claim [[42]] 7; and

b) at least one component to detect hybridization of the isolated nucleic acid to a 12q23-qter nucleotide sequence.

59. (currently amended) A kit for detecting a 12q23-qter nucleotide sequence comprising:

a) the isolated nucleic acid according to claim [[46]] 11; and

b) at least one component to detect hybridization of the isolated nucleic acid to a 12q23-qter nucleotide sequence.

60-125. (cancelled)